REGENXBIO, Inc. Forecast, price target & analysts
REGENXBIO, Inc. Target price 2026 - Analyst rating & recommendation
REGENXBIO, Inc. Classifications & Recommendation
REGENXBIO, Inc. Price Target
| Target Price | $20.40 |
| Price | $7.43 |
| Potential |
174.56%
register free of charge
|
| Number of Estimates | 14 |
|
14 Analysts have issued a price target REGENXBIO, Inc. 2027 .
The average REGENXBIO, Inc. target price is $20.40.
This is
174.56%
register free of charge
$52.50
606.59%
register free of charge
$10.10
35.94%
register free of charge
|
|
| A rating was issued by 19 analysts: 16 Analysts recommend REGENXBIO, Inc. to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the REGENXBIO, Inc. stock has an average upside potential 2027 of
174.56%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 170.44 | 169.63 |
| 104.54% | 0.48% | |
| EBITDA Margin | -85.36% | -96.17% |
| 66.78% | 12.67% | |
| Net Margin | -113.75% | -109.78% |
| 58.26% | 3.49% |
14 Analysts have issued a sales forecast REGENXBIO, Inc. 2026 . The average REGENXBIO, Inc. sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an REGENXBIO, Inc. EBITDA forecast 2026. The average REGENXBIO, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
14 REGENXBIO, Inc. Analysts have issued a net profit forecast 2026. The average REGENXBIO, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.76 | -3.44 |
| 18.08% | 8.51% | |
| P/E | negative | |
| EV/Sales | 3.34 |
14 Analysts have issued a REGENXBIO, Inc. forecast for earnings per share. The average REGENXBIO, Inc. EPS is
This results in the following potential growth metrics and future valuations:
REGENXBIO, Inc....
Current REGENXBIO, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Baird |
Locked
➜
Locked
|
Locked | Aug 25 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 25 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 10 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 24 2026 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Jun 22 2026 |
| Baird |
Locked
➜
Locked
|
Locked | Jun 22 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Baird:
Locked
➜
Locked
|
Aug 25 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 25 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 10 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 24 2026 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Jun 22 2026 |
|
Locked
Baird:
Locked
➜
Locked
|
Jun 22 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
